

## Marbocyl S

### Description:

100mL of sterile, aqueous solution containing 10% w/v of Marbofloxacin as active ingredient and 0.1% w/v monothioglycerol and 0.2% w/v m-cresol as preservatives and 0.01% w/v disodium edetate as chelating agent.

### Indications:

In cattle: Marbofloxacin S is indicated in the treatment of respiratory and other infections caused by susceptible strains of organisms.

### Dosage:

The recommended dosage is 8 mg/kg (4mL/50kg bw) by intramuscular injection in cattle. Do not exceed 20mL per injection site.

### Pharmacological Properties:

Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group, which acts by inhibition of DNA gyrase. It is effective against a wide range of Gram positive bacterial (in particular *Staphylococci*) and Gram negative bacteria (*Escherichia coli*, *Salmonella typhimurium*, *Citrobacter freundii*, *Enterobacter Cloacae*, *Serratia marcescens*, *Morganella morganii*, *Proteus spp*, *Kelbsiella spp*, *Shlgella spp*, *Pasteurella spp*, *Haemophilus spp*, *Moraxella spp*, *Pseudomonas spp*, *Brucella canis*) as well as *Mycoplasma spp*.

After subcutaneous or intramuscular administration in cattle and intramuscular administration in pigs at the recommended dose of 2mg/kg, marbofloxacin is readily absorbed and reaches maximal plasma concentrations of 1.5 ug/mL within less than 1 hour.

Its bioavailability is close to 100%.

It is weakly bound to plasma proteins (less than 10% in pigs and 30% in cattle), extensively distributed and in most tissues (liver, kidney, skin, lung, bladder, uterus) it achieves higher concentrations than in plasma.

In cattle, marbofloxacin is eliminated slowly in pre-ruminating calves ( $t_{12} = 4-7$  hours) predominantly in the active form in urine and faeces (3/4 in pre-ruminating calves, 1/1 in ruminants).

### Withdrawal Periods:

Milk intended for human consumption must be discarded during treatment and for 5 milkings (3 days) following the last treatment.

Cattle producing meat and offal for human consumption must not be slaughtered during or within 6 days of the last treatment.

It is an offence for users of this product to cause residues exceeding the relevant MRL (Maximum Residue Limits of Agricultural Compounds) in the New Zealand Food Standards.

### Warnings and Further Information:

Administration by the intramuscular route may cause transient local reactions such as pain and swelling at the injection site and inflammatory lesions which persist at least 12 days after injection.

No further undesirable effects have been observed in cattle.

Safety of this product has not been assessed in lactating cows.

Safety of this product has not been assessed in animals under 12 months.

Overdosage may cause signs in the form of acute neurological disorders which would have to be treated symptomatically.

Indiscriminate use of the product could contribute to the development of antibiotic resistance. The product should only be used in individual cases of serious infections that are not likely to respond to any other antibiotic.

## Marbocyl S (cont)

The product must not be used to treat groups of food producing animals unless bacteriology has confirmed the diagnosis and sensitivities have shown that it is the only alternative that is likely to be effective.

Following withdrawal of the first does, use the product within 28 days.

Registered pursuant to the ACVM Act 1997,  
No A10444  
**RESTRICTED VETERINARY MEDICINE**  
Marbocyl S  
For Animal Treatment Only



Ethical Agents Veterinary Marketing Ltd, 54 Hobill Ave, Manukau, 2104, New Zealand.  
P O Box 97110, Manukau City, Manukau, 2241, New Zealand.  
Telephone 64-9-262 1388, Fax 64-9-262 1411, Freephone 0800 800 624.  
E-mail [eage@xtra.co.nz](mailto:eage@xtra.co.nz), Website [www.ethicalagents.co.nz](http://www.ethicalagents.co.nz).

